Investigating the Outcomes in Patients with high-risk diffuse large B-cell lymphoma Treated with Central Nervous System Prophylaxis

Investigating the Outcomes in

Patients with high-risk diffuse large

B-cell lymphoma Treated with

Central Nervous System Prophylaxis:

An Intercontinental Multicentre

Clinical Study – The First 44 Years

Findings from 1955 to 1999

Kingsley O. D. E. C¹, Kingsley O. K¹, Smith S. M² and Morgan M²

1. London Medical Academy Research Consortium, London, England, United Kingdom

2. Santa Maria Research Consortium, Vienna, Austria, Europe

Abstract

The burden of diffuse large B-cell lymphoma (DLBCL) is significant due to its high frequency as the most common form of non-Hodgkin lymphoma (NHL), its aggressive nature, and the challenges in treating patients who relapse. It represents a substantial medical burden, causing high healthcare costs, especially for relapsed or refractory cases, and imposing physical, emotional, and financial burdens on patients and their families.  The aim of this study is to investigate the outcomes in patients with high-risk diffuse large B-cell lymphoma treated with CNS prophylaxis. This is a work in progress.

Keywords: Primary central nervous system lymphoma, PCNSL, prognostic elements, diagnosis, treatment, diffuse large B-cell lymphoma, DLBCL.

Paper Published in the Royal College of General Practitioners, North and West London Faculty Magazine, Volume 1, Number 8, 1999. This publication is available at the British Library, Legal Deposit Office.